Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5โyears?
<p><b>INTRODUCTION</b></p><p>Cancer cachexia is a multifactorial syndrome affecting up to 80% of advanced cancer patients, associated with poor quality of life, increased cancer-treatment toxicity, and reduced survival. Despite its clinical burden, no FDA- or EMA-approved pharmacologic therapies currently exist.</p><p><b>AREAS COVERED</b></p><p>This review...
